Speakers - Sachs Associates

CONTACT
Carlos Paya
Chief Executive Officer
ADDRESS
1124 Columbia Street suite 700
Seattle, WA 98104
TELEPHONE
206-826-7910
FAX
206-682-0648
EMAIL
carlos.paya@immunedesign.com
YEAR FOUNDED
2008
Immune Design
www.immunedesign.com
FINANCIAL SUMMARY
Since 2008 Immune Design has raised $52M from venture capital funding.
COMPANY PROFILE
Immune Design is a privately held biotechnology company based in Seattle, Washington and formed in 2008
to bring together some of the world’s leaders in the field of immunology, and their technologies, to develop
therapeutic vaccines for the treatment of infectious and malignant disease. The company’s scientific founders
are Dr. David Baltimore (Past President of Caltech, Rockefeller University, and the Whitehead Institute and the
Co-Recipient of the 1975 Nobel Prize in Physiology or Medicine), Dr. Steven Reed (Past Co-founder and CSO
of Corixa and Founder/CEO of the Infectious Diseases Research Institute), and Dr. Larry Corey (President and
Director of the Fred Hutchinson Cancer Research Center and Professor of Medicine and Laboratory Medicine at
the University of Washington). To date Immune Design has raised approximately $52 million from The Column
Group, Alta Partners, Versant Ventures, and Proquest.
Immune Design leverages its unique vaccine technologies to precisely control the activation and context of
antigen presentation by dendritic cells in order to shape the desired adaptive immune response. The first
technology is a novel adjuvant for recombinant protein antigen (rP)-based vaccines comprising Glucopyranosyl
Lipid A (GLA), a synthetic TLR4 agonist, formulated in a stable 2% oil-in-water emulsion (SE). Adjuvants can play
an important role in vaccine therapies by stimulating the immune system’s response to the target antigen. GLA
is the first ‘designer adjuvant’ and was developed by Immune Design co-founder Dr. Steve Reed. To date GLA-SE
has been safely administered in over 300 human subjects.
Our second vaccine platform is a novel lentivirus-based vector, ID-LV (Immune Design-Lentiviral Vector). The
prototype of ID-LV was developed by Immune Design co-founder, Dr. David Baltimore. ID-LV is unique in that it
can stimulate the body’s own dendritic cells (DCs), the “sentinels” of the immune system, to produce any, and
importantly, multiple antigens of interest in the same product configuration, effectively orchestrating the human
immune system to respond to targeted diseases. Immune Design’s ID-LV and GLA-SE vaccine technologies
are immunologically synergistic, as documented in animal models, and thus, have the potential to be used both
alone and in combination to create the next generation of vaccines for diseases with unmet medical need.
MANAGEMENT
Carlos Paya, MD, PhD, Chief Executive Officer
Wayne Gombotz, PhD, Chief Development Officer
J Paul Rickey, VP, Finance and Administration
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS